You are are top of everything.

Julie Cherrington was hired July 23, 2014 and left Apr 30, 2015. I wondered why the short tenure. I suspect there must have been strategic differences. Anyway, it was a lot of talent and depth to lose. My guess was that she was too talented for Don to handle. Pure speculation on my part.

Julie M Cherrington, PhD is currently the Chief Executive Officer of QUE Oncology, a clinical stage company developing novel non-hormonal treatments for vasomotor symptoms in postmenopausal women, and in cancer patients receiving hormone therapy; a position she has held since September 2020. She has served on the QUE Board of Directors since July 2019.

Dr Cherrington, is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®.

Dr. Cherrington previously has served as President and Chief Executive Officer at several other oncology companies, including Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation, a diabetes and antiviral company. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company.

Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.

Dr. Cherrington is a member of the Scientific Advisory Board of the Clearity Foundation and is an advisor in entrepreneurship initiatives at CLSI, UC San Francisco, UC Davis and Equalize 2020 and 2021. Currently, she serves on the Boards of Sardona Therapeutics, Rakovina Therapeutics, Kisoji Biotechnology, QUE Oncology, Vaxart, and Mirati Therapeutics.

Lets hope that Sanjay stays put and has a significant influence over the direction of the business. I now believe that Don is completely lost.

GLTA

Toinv